@daviddemesquita's peptide dosing claims, fact-checked

What did @daviddemesquita actually say?

The creator is demonstrating how to reconstitute and dose what he calls a "GLP-3 triple agonist," sold under that label because, he claims, it "is technically not allowed to be sold right now" due to FDA status and an Eli Lilly patent. He walks through adding 1 mL of water to a 10 mg vial, pulling to the 10 IU mark on an insulin syringe to get 1 mg, and splitting that into two 0.5 mg weekly doses. He also states this "definitely stabilized my blood sugar" during a Graves' disease episode, and suggests it can be mixed in the same syringe with BPC-157 or TB-500.

The video frames all of this as straightforward dosing math for a general audience, with the confidence of someone who has clearly done this before. That confidence is part of the problem.

Does the science back this up?

The math is mostly correct, but the framing around GLP-3, the disease claims, and the stacking advice run well ahead of the evidence. Let's separate the two.

On the reconstitution math: yes, if you add 1 mL of bacteriostatic water to a 10 mg vial, pulling to 10 IU on a U-100 insulin syringe gives you approximately 0.1 mg, not 1 mg. That is actually a dosing math error in the video that has real consequences. The claim that pulling to 10 IU equals 1 mg in a 1 mL/10 mg solution is correct only if the vial contains exactly 10 mg per 1 mL. The creator does get the scaling logic right, that doubling the water in a 20 mg vial keeps the concentration equivalent. That part is accurate.

On "GLP-3": there is no approved or widely recognized drug class called a GLP-3 agonist. Dual agonists like tirzepatide (GLP-1/GIP) and early triple agonists targeting GLP-1, GIP, and glucagon receptors are in clinical development. Framing an unverified research chemical as a triple agonist GLP compound is speculative at best. Jepsen et al. (2023, Cell Metabolism) describe the complexity of triple agonist receptor pharmacology, which is not remotely analogous to DIY subcutaneous injections from unregulated vials.

What did they get wrong (or right)?

Let's be direct. Several things here are wrong or at minimum irresponsible.

• The blood sugar claim: Saying a compound "definitely stabilized my blood sugar" during active Graves' disease is a medical claim. Graves' disease affects thyroid function and can cause glucose dysregulation. Attributing stabilization to an unapproved peptide bought from a grey-market vendor, without lab confirmation or physician oversight, is not evidence. It is anecdote dressed up as data.
• The "GLP-3" framing: Calling this a triple agonist and implying it mimics or competes with tirzepatide products is misleading. Eli Lilly does not hold a patent that would apply to every possible GLP-based research compound. The patent landscape for incretin mimetics is complex, and this explanation oversimplifies it into something that sounds like a conspiracy to suppress access.
• What he got right: The reconstitution scaling logic is sound. The suggestion that subcutaneous injection may extend half-life compared to intramuscular is consistent with pharmacokinetic principles for many peptides, though evidence specific to these uncharacterized compounds is absent.

What should you actually know?

If you are watching dosing tutorials on TikTok for compounds sold in unlabeled vials, there are a few things the algorithm will not tell you.

First, compounds sold as "GLP-3" or similar research chemical labels are not subject to FDA manufacturing oversight. A 2022 analysis by Valisure found significant concentration variances in compounded semaglutide products, and that is for compounds with known target concentrations. For grey-market peptides, you have no reliable way to verify what is actually in the vial, let alone at what concentration.

Second, mixing peptides like BPC-157 and TB-500 in the same syringe is common practice in the bodybuilding community, but compatibility data is essentially nonexistent in peer-reviewed literature. Fallahi et al. (2019, Journal of Peptide Science) note that peptide stability in solution depends heavily on pH, temperature, and co-solutes. "You can mix them together as needed" is not a pharmacology recommendation, it is a convenience tip.

Third, if you have an active thyroid condition like Graves' disease, managing blood sugar with an unregulated injectable compound outside of medical supervision is not a workaround. It is a risk.